Consequently, hOAT has emerged as a potential target for developing effective treatments for different types of cancers; therefore, we are interested in determining the mechanistic differences among compounds that inactivate both GABA-AT and hOAT for the future design of selective inactivators of either GABA-AT or hOAT as potential therapeutics. The gene discussed is ABAT; the disease is cancer.